
PRESS RELEASE

PharmaBiome and Roquette announce a collaboration to study the prebiotic potential of fibers.

This partnership will contribute to develop brand new Nutrition and Health ingredients

Zurich, September 30 2017. PharmaBiome and Roquette announced today an agreement to use PharmaBiome's proprietary platform technology to identify the prebiotic potential of specific natural-based fibers under study by Roquette.

PharmaBiome, an innovative young company in the microbiome field, with a strong pipeline for anaerobic culture and characterization and Roquette, a global leader in natural-based ingredients, started this new partnership in July 2017. The collaboration aims at understanding the prebiotic potential of specific plant-based fibers through the development of a rapid screening tool.

The results of these studies will provide new information for the development of innovative ingredients with scientifically proven health benefits for Food and Nutrition markets.

A large body of scientific evidence, identified the intestinal microbiota as a key contributor to human health and well-being. Changes in its composition are known to have serious health consequences, including chronic inflammatory and immune diseases. Prebiotics are fibers that stimulate the growth of beneficial bacteria and can be used to positively influence the microbiota composition. So far, limited understanding of their indirect effects on the microbiome has constrained the successful implementation of prebiotics as therapeutics.

Financial terms of this agreement were not disclosed.

Dr. Tomas de Wouters, CEO and co-founder of PharmaBiome commented: "*This collaboration with Roquette represents an additional promising application of PharmaBiome's platform technology, expanding our understanding of the microbiome and its utilization to the field of prebiotics.*"

Statement from Roquette: Sergio Neves, Head of Nutrition & Health R&D at Roquette: "*This project with Pharmabiome will allow Roquette to have access to innovative and technological tools in order to study the interaction between our innovative ingredients and the gut microbiota. We are very pleased to launch this collaboration, which reinforces our commitment to delivering sustainable innovative solutions to the Food, Nutrition and Health sectors.*"

About PharmaBiome:

PharmaBiome is a spin-off company of ETH Zurich, commercializing a unique and innovative technology platform that is able to isolate, cultivate and assemble bacterial strains of the human gut microbiome. PharmaBiome is developing therapeutic consortia of gut bacteria as innovative, standardized and safe products to treat diseases resulting from an unbalance of

the intestinal microbiota with a high and currently unmet medical need.

About Roquette: “Improving well-being by offering the best of nature”

A family-owned Group serving customers globally, Roquette is a leader in specialty food ingredients and pharmaceutical excipients. The products and solutions developed by the Group deliver proven technological, nutritional and health benefits precisely tailored to the pharma, nutrition, food and selected industry markets. Roquette’s offer is produced from plant-based raw materials such as corn, wheat, potatoes and peas. Since its foundation over 80 years ago, the Group’s growth has been based on innovation, a passion for the job and a commitment to achieve. Roquette operates in over 100 countries, has a turnover of around 3.2 billion euros and currently employs more than 8,000 people worldwide.

For further information please contact:

PharmaBiome AG:
Dr. Tomas de Wouters, CEO
t.dewouters@pharmabiome.com
+44 (0) 44 632 86 22

Roquette: Media Contact
Carole Petitjean
carole.petitjean@roquette.com
+ 33 (0) 3 21 63 36 00